Some CDC data and webpages still offline after judge's order
Some data and webpages taken down by the Centers for Disease Control and Prevention and other federal health agencies to comply with President Trump's executive order remained offline Thursday, after a judge ordered health officials to put some back online.
Agency officials had scrambled last month to scrub all mentions of "gender" from their websites, taking down anything that could not be easily rewritten.
That prompted a lawsuit by the nonprofit Doctors for America, which secured a federal court ruling to temporarily restore the list of webpages that the group had cited in their filings by the end of the day on Tuesday.
However, access to federal health resources on several topics not specifically mentioned by the group has not been restored, like the CDC's recommendations on who should be vaccinated for mpox during the ongoing outbreak, which remains offline.
The ruling this week by Judge John Bates said federal agencies have until Friday to restore access to any other resources that members of the doctors group say they "rely on to provide care" that were removed without notice.
Some datasets the group's members said they needed, like a CDC survey of mental health and chronic disease in high school students, were accessible again by Thursday.
But an online tool to navigate results from a similar dataset overseen by the agency about adults, the Behavioral Risk Factor Surveillance System, was still offline.
Researchers rely on that survey's results to compare a number of health trends across different states and communities, including rates of cancer screening, obesity rates and women's health issues.
Webpages mentioning "gender" on other health agency websites also remain offline. The Office of Disease Prevention and Health Promotion's "Healthy People 2030" database of goals tracked by federal health authorities also remains partially offline.
Pages about data on transgender people, like goals to reduce bullying of transgender students or increase the national surveys that include data on transgender people, remain inaccessible.
The FDA's posts on how it was easing restrictions for gay men to donate blood also remain offline, after they were taken down last month. The agency's final guidance to blood banks can still be found by searching the FDA website, but it has been quietly scrubbed of all mentions of gender.
"Maintaining a safe and adequate supply of blood and blood products in the U.S. is paramount for the FDA, and this proposal for an individual risk assessment, regardless of gender or sexual orientation, will enable us to continue using the best science to do so," FDA Commissioner Robert Califf had said in a now-deleted announcement from 2023 about the change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US Health Secretary Kennedy guts vaccine advisory committee
By Ahmed Aboulenein, Michael Erman and Julie Steenhuysen WASHINGTON (Reuters) -Health Secretary Robert F. Kennedy Jr. has fired all 17 members of a U.S. Centers for Disease Control and Prevention panel of vaccine experts and is in the process of replacing them, his department said on Monday, drawing protest from many vaccine scientists. The move is the most far-reaching in a series of actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine. Scientists and experts said the changes to the vaccine panel, which recommends how vaccines are used and by whom, would undermine public confidence in health agencies. Kennedy promised the move would raise public confidence. "Today we are prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda," Kennedy said in a statement from the Department of Health and Human Services. Kennedy has for years sown doubt about the safety and efficacy of vaccines, but he pledged to maintain the country's existing vaccine standards to secure his appointment in President Donald Trump's administration. The Food and Drug Administration, which is overseen by Kennedy's department, has approved a number of vaccines during his tenure despite concerns over his stances. Even so, at least one senior Republican member of Congress expressed doubts about the changes in the panel. Kennedy said the Advisory Committee on Immunization Practices is rife with conflicts and has never turned down a vaccine, even though the decision to approve vaccines rests with the U.S. Food and Drug Administration. The CDC panel provides guidance to the CDC on which groups of people would most benefit from an already-approved vaccine. "That's a tragedy," said former FDA Chief Scientist Jesse Goodman. "This is a highly professional group of scientists and physicians and others... It's the kind of political meddling that will reduce confidence rather than increase confidence." The Pharmaceutical Research and Manufacturers of America called Kennedy's action concerning for public health. "Upending the ACIP membership increases uncertainty and vaccine skepticism, undermining the health gains achieved through vaccination," the industry body said in a statement late on Monday. Shares of vaccine makers Moderna and U.S.-listed shares of BioNTech fell more than 1%, while Pfizer was down marginally in extended trading on Monday. Kennedy said most panel members receive funding from drugmakers although members are required to declare any potential or perceived conflicts of interest that arise in the course of their tenure and any relevant business interests, positions of authority or other connections with organizations relevant to the committee's work. Kennedy and HHS provided no specific evidence of industry conflicts of interest among departing ACIP members. The CDC's web page for conflicts of interest, last updated in March, showed that one current member had recused herself from votes on a handful of vaccines because she had worked on clinical trials for their manufacturers. BIDEN APPOINTEES All 17 ACIP members were appointed under former President Joe Biden's administration, including 13 in 2024, HHS said. Without their removal, Trump's administration would not have been able to choose a majority of the committee until 2028. "This is not a political committee, it's never been partisan," said Dorit Reiss, a vaccine law expert at UC Law San Francisco. "It's an expert committee. Presidents have never been involved in ACIP membership." The decision drew criticism from Democrats in Congress, and one key Republican expressed concern. "Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion," said Republican U.S. Senator Bill Cassidy in a post on X. "I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case." Cassidy, a doctor from Louisiana who had expressed wariness about Kennedy's anti-vaccine views before clearing the path for him to become the nation's top health official, said at the time he had received assurances Kennedy would protect existing vaccination programs. The CDC panel will convene its next meeting June 25-27 at CDC headquarters in Atlanta, the department said. Vetting new panel members typically takes months, said one expert with close ties to the committee, who expressed doubts the newly appointed panel would be able to meet on time unless Kennedy and his team "have been working in the shadows" to onboard them months ahead of the announcement. Kennedy has drawn condemnation from health officials for his vaccine policies including what they say is a weak endorsement of the measles shots during an outbreak that has infected more than 1,000 mostly unvaccinated people and killed three. He announced last month the government was dropping its recommendation that healthy children and pregnant women should receive COVID shots, sidestepping the typical process. Traditionally, once the FDA approves vaccines for sale to the public, ACIP's role is to review data in a public meeting and vote on vaccine recommendations, which are then sent to the CDC director to sign off. The Affordable Care Act generally requires insurers to cover vaccines that are listed on the CDC vaccine schedules for adults and children. The recommendations also determine which vaccines the CDC's Vaccines for Children program will provide free of charge to those without insurance.
Yahoo
2 hours ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
